Curated Optogenetic Publication Database

Abstract: Optoswitches are of particular interest to the metabolic engineering community, as light has a superior advantage of tunability and reversibility. However, the light-shading effect at industrial scales remains an unsolved challenge. Here, we report optogenetic quorum-sensing (OptoQS) circuits to induce and maintain a sustained gene expression at the population level by transient light stimulation. In particular, we reprogram the pheromone-responsive G-protein coupled receptor (GPCR) signaling cascade in Saccharomyces cerevisiae to effectively record transient light inputs. Once the transient light input is recorded as a form of α-factor accumulation, the surrogate messenger can diffuse and transmit the signal across the cell population. Eventually, we successfully demonstrated the utility of the OptoQS circuit for metabolic regulation of 3-hydroxypropionate biosynthesis. Based on the promising results from OptoQS circuits, we envision that the flexibility of our design might be explored for the future fabrication of various genetic circuits to record other transient physical stimuli.

Abstract: Engineered bacteria-based cancer therapy has increasingly been considered to be a promising therapeutic strategy due to the development of synthetic biology. Wherein, engineering bacteria-mediated photodynamic therapy (PDT)-immunotherapy shows greater advantages and potential in treatment efficiency than monotherapy. However, the unsustainable regeneration of photosensitizers (PSs) and weak immune responses limit the therapeutic efficiency. Herein, we developed an engineered bacteria-based delivery system for sequential delivery of PSs and checkpoint inhibitors in cancer PDT-immunotherapy. The biosynthetic pathway of 5-aminolevulinic acid (5-ALA) was introduced into Escherichia coli, yielding a supernatant concentration of 172.19 mg/L after 10 h of growth. And another strain was endowed with the light-controllable releasement of anti-programmed cell death-ligand 1 nanobodies (anti-PD-L1). This system exhibited a collaborative effect, where PDT initiated tumor cell death and the released tumor cell fragments stimulated immunity, followed by the elimination of residual tumor cells. The tumor inhibition rate reached 74.97%, and the portion of activated T cells and inflammatory cytokines were reinforced. The results demonstrated that the engineered bacteria-based collaborative system could sequentially deliver therapeutic substance and checkpoint inhibitors, and achieve good therapeutic therapy. This paper will provide a new perspective for the cancer PDT-immunotherapy.